Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24185230 | 1.00 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1HPGDHRH3POLB | |
| SCHEMBL24185235 | 1.00 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1HPGDHRH3POLB | |
| SCHEMBL26773746 | 0.92 | L3MBTL3 (0.84) | L3MBTL3L3MBTL1HPGDHRH3POLB | |
| SCHEMBL10195734 | 0.88 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1HPGDHRH3KMT2A | |
| SCHEMBL12237837 | 0.88 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1HPGDHRH3KMT2A | |
| SCHEMBL12237840 | 0.88 | L3MBTL3 (0.71) | L3MBTL3L3MBTL1HPGDHRH3KMT2A | |
| SCHEMBL24185218 | 0.87 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1HRH3PDK2MGLL | |
| SCHEMBL22165523 | 0.87 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1HRH3PDK2MGLL | |
| SCHEMBL2987028 | 0.87 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1HRH3PDK2JAK2 | |
| SCHEMBL1447249 | 0.87 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1HRH3PDK2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| WO-2022011338-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022011337-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| US-7842715-B2 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842715-B2 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842715-B2 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2027086-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth (US) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007136668-A9 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH CORP (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007136668-A9 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH CORP (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007136668-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136668-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | L3MBTL3 2148/4885L3MBTL1 2031/4885HPGD 4226/4885 |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | HRH4, HRH3, HRH2 | L3MBTL3 2436/4885L3MBTL1 3689/4885HPGD 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.